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Abstract
Background: The Chinese government has provided health services to those infected by the human
immunodeficiency virus (HIV) under the acquired immunodeficiency syndrome (AIDS) care policy since 2003.
Detailed research on the actual expenditures and costs for providing care to patients with AIDS is needed for
future financial planning of AIDS health care services and possible reform of HIV/AIDS-related policy. The purpose
of the current study was to determine the actual expenditures and factors influencing costs for untreated AIDS
patients in a rural area of China after initiating highly active antiretroviral therapy (HAART) under the national Free
Care Program (China CARES).
Methods: A retrospective cohort study was conducted in Yunnan and Shanxi Provinces, where HAART and all
medical care are provided free to HIV-positive patients. Health expenditures and costs in the first treatment year
were collected from medical records and prescriptions at local hospitals between January and June 2007.
Multivariate linear regression was used to determine the factors associated with the actual expenditures in the first
antiretroviral (ARV) treatment year.
Results: Five ARV regimens are commonly used in China CARES: zidovudine (AZT) + lamivudine (3TC) + nevirapine
(NVP), stavudine (D4T) + 3TC + efavirenz (EFV), D4T + 3TC + NVP, didanosine (DDI) + 3TC + NVP and combivir +
EFV. The mean annual expenditure per person for ARV medications was US$2,242 (US$1 = 7 Chinese Yuan (CNY))
among 276 participants. The total costs for treating all adverse drug events (ADEs) and opportunistic infections
(OIs) were US$29,703 and US$23,031, respectively. The expenses for treatment of peripheral neuritis and
cytomegalovirus (CMV) infections were the highest among those patients with ADEs and OIs, respectively. On the
basis of multivariate linear regression, CD4 cell counts (100-199 cells/μL versus <100 cells/μL, P = 0.02; and ≥200
cells/μL versus <100 cells/μL, P < 0.004), residence in Mangshi County (P < 0.0001), ADEs (P = 0.04) and OIs (P =
0.02) were significantly associated with total expenditures in the first ARV treatment year.
Conclusions: This is the first study to determine the actual costs of HIV treatment in rural areas of China. Costs for
ARV drugs represented the major portion of HIV medical expenditures. Initiating HAART in patients with higher
CD4 cell count levels is likely to reduce treatment expenses for ADEs and OIs in patients with AIDS.
Background
According to the most recent estimates by the Ministry
o fH e a l t ha n dt h eJ o i n tU n i t e dN a t i o n sP r o g r a mo n
HIV/AIDS (UNAIDS), China had 560,000-920,000 peo-
ple living with human immunodeficiency virus (HIV)
and 97,000-112,000 people living with acquired immu-
nodeficiency syndrome (AIDS) as of the end of 2009.
A total of 320,000 HIV/AIDS cases have been reported
from the national infectious disease surveillance system
from 1985 to 2009 [1]. The first wave of AIDS cases
was reported in China around 2002, and the majority of
these AIDS patients contracted the virus in the 1990s,
through either the injection of drugs or plasma dona-
tion. In response, the Chinese government launched the
China Comprehensive AIDS Response (CARES) in 2003,
* Correspondence: maple23@hotmail.com
1State Key Laboratory for Molecular Virology and Genetic Engineering,
Institute of Pathogen Biology, Chinese Academy of Medical Science, Peking
Union Medical College, Beijing, PR China
Full list of author information is available at the end of the article
Zhou et al. BMC Medicine 2011, 9:6
http://www.biomedcentral.com/1741-7015/9/6
© 2011 Zhou et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.a community-based HIV treatment, care and prevention
program that provides free HIV treatment, including
antiretroviral (ARV) therapy and treatment of opportu-
nistic infections (OIs) to the indigent in urban areas and
to everyone in rural areas [2].
China CARES provides first-line ARV regimens,
including two nucleoside reverse transcriptase inhibitors
(NRTIs) and one non-nucleoside reverse transcriptase
inhibitor (NNRTI), the generics of which are produced
in China. According to national guidelines, ARV treat-
ment is provided by designated infectious disease hospi-
tals, and patients in rural areas in some provinces may
go to village clinics to receive counseling and treatment
for OIs. Staff from the local Centers for Diseases Con-
trol and Prevention (CDC) provides education on ARV
treatment compliance and disease prevention interven-
tion. An estimated 97% of AIDS patients (>50,000) who
initiated highly active antiretroviral therapy (HAART) in
China received free treatment through this national pro-
gram by 2008; 3% of these patients received treatment
via self-pay or through some nongovernmental organiza-
tion-sponsored treatment programs that may use differ-
ent regimens [3,4]. The central government increased
funding for HIV prevention and treatment from US$56
million in 2003 to US$142 million in 2008, while local
governments increased funding from US$14 million to
US$86 million in the same period [1]. Recent analyses
of national data from China CARES have shown that it
significantly decreased mortality among HIV-infected
patients from 27 deaths per 100 person-years before
treatment to 4-5 deaths per 100 person-years after
6 months of HAART [3,5].
The Comprehensive International Program for
Research on AIDS (CIPRA) is an initiative sponsored by
the U.S. National Institutes of Health (NIH). China
CIPRA comprises five interrelated projects. The overall
goal of China CIPRA is to strengthen the existing HIV
research infrastructure in China and to build the capa-
city to conduct multidisciplinary research to explore
promising strategies for HIV prevention, treatment and
control. Subproject 4 is “A Feasibility Study of Lamivu-
dine/Zidovudine (3TC/ZDV) plus Efavirenz (EFV) as
Initial Therapy of HIV-1-infected Patients in Rural
Areas of China.” The project was conducted between
June 2005 and June 2007. The primary objective of Sub-
project 4 was to determine the efficacy and safety of a
potent combination ARV regimen (3TC/ZDV + EFV)
for the treatment of HIV-1-infected patients in a rural
area of China. China CIPRA covered all of the costs for
patients during the research period.
However, there are no publications on the expendi-
tures and cost-effectiveness of treating HIV-infected
patients in China. Considering the fact that treatment
providers, targeted clients and economic assistance
policies may vary across different areas, the actual
expenditures of this program are largely unknown. Such
information is needed for future financial planning and
possible reform of AIDS-related policies. Therefore, the
current study determined the expenditures associated
with two ARV treatment programs in rural China.
Methods
Study Settings
This retrospective cohort study was conducted in two geo-
graphical areas: Dehong Prefecture of Yunnan Province in
southwestern China and Wenxi County of Shanxi Pro-
vince in central China. Enrollment criteria and follow-up
periods were slightly different at the two study sites. The
HIV/AIDS epidemic in Dehong Prefecture primarily con-
sists of injecting drug users (IDUs) and female sex workers
and their clients [5]; Mangshi, Ruili, and Longchuan coun-
ties in Dehong Prefecture were also included in the study.
Patients were enrolled into the China CARES program in
Dehong Prefecture if they met the following criteria: the
World Health Organization (WHO)’s clinical stage III or
IV, CD4 cell count <200 cells/μL, and ≥18 years of age.
Patients were treated following the national guidelines [6]
using one of four ARV regimens: AZT + 3TC + nevirapine
(NVP), stavudine (D4T) + 3TC+ EFV, D4T + 3TC + NVP
or didanosine (DDI) + 3TC + NVP. After initiating ARV
therapy, patients were scheduled to have subsequent clinic
visits at intervals of 2 weeks and 1, 2, 3, 6, 12, 18 and
24 months.
The HIV epidemic in Wenxi County of Shanxi Pro-
vince was caused by nonhygienic plasma collection [7].
Wenxi County is the site of China CIPRA Subproject 4.
China CIPRA Subproject 4 is a single-arm, open-label
clinical trial to evaluate the impact of ARV treatment on
the progression of HIV. The eligibility criteria for parti-
cipating in the trial were as follows: WHO’s clinical
stage III or IV, CD4 cell count <350 cells/μLa n d≥18
years of age. The ARV regimen was combivir (AZT
+3TC) + EFV. Patients were scheduled for follow-up
c l i n i cv i s i t sa tw e e k s1 ,2 ,3 ,4 ,8 ,1 2 ,2 4 ,3 6 ,4 8a n d5 2
after initiating ARV treatment.
The costs incurred in the first year of HAART were
difficult to determine because of the range of signs and
symptoms of AIDS. Therefore, participants who had not
received HAART at the time of enrollment were
included in our analysis. The eligible patients were
screened and enrolled at Mangshi, Ruili and Longchuan
hospitals as designated by the Dehong Prefecture Health
Bureau in the China CARES program, and at Wenxi
County Hospital Clinic as designated by China CIPRA.
Data Collection
Data were collected from January to June 2007 in desig-
nated hospitals in the four participating counties.
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who had integrated treatment expenditure materials in
China CARES were randomly selected based on their
treatment identification numbers in Dehong Prefecture.
Two researchers were trained to review medical records
and billing files using predesigned data collection forms.
The following data were collected: demographics (age,
gender, marital status, ethnic group, level of education,
occupation, residential status and drug use), baseline
CD4 cell count, date of antiretroviral medication (ARV)
initiation and termination, ARV regimen, adverse drug
events (ADEs), OIs and itemized costs. Expenditure data
were collected starting from patient entry to ARV treat-
ment until the end of the first year in Yunnan and
Shanxi. Our study was approved by the Institutional
Review Board of the Institute of Pathogen Biology,
Chinese Academy of Medical Science. Written informed
consent was provided from all patients when they
initiated HAART.
ARV drugs are directly managed by the Provincial
Center of Disease Control and Prevention or Medical
Politics Division and distributed to the designated hospi-
tal. Thus, it is easy to calculate the cost of ARV drugs.
However, there is no consistent data management sys-
tem for Chinese medical insurance. Data collection in
our study required substantial effort. To retrieve accu-
rate expenditure data, we printed every patient’sb i l l
from the designated hospital financial management
computer system. All items in the bills were categorized
according to the diagnosis of OIs and ADEs. All patients
who needed hospitalization were referred to a county-
level hospital within our study sites. Therefore, we were
able to obtain all inpatient expense data from the desig-
nated hospital. Outpatient expenses for ADEs or OIs at
designated hospitals were also obtained in the same
manner. Outpatient expenses for ADEs or OIs at town-
ship hospitals or village clinics were calculated by the
designated hospital. We also separated these expenses
according to diagnosis. All the items were classified as
follows: medications, laboratory testing and ancillary
examinations and medical service charges. The price of
every item was based on the medical charge standard
established by the local health bureau. The outpatient
and inpatient expenses were averaged by the number of
patients who experienced ADEs or OIs.
Calculation of expenditures
The expenditures during the first treatment year were
included for analyses, which were divided into four
parts: (1) ARV medications; (2) other medications for
prophylaxis and treatment of ADEs or OIs; (3) labora-
tory tests at baseline and follow-up for monitoring of
ARVs safety and efficacy, such as CD4 and CD8 cell
counts, hematologic parameters, chemistries, pregnancy
testing, liver function tests, amylase activity, creatine
kinase level, urinalysis and radiologic examinations
(chest X-ray and abdominal ultrasound); and (4) other
items, including nursing, infusions, bed use, counseling,
blood transfusions and medical consumer goods.
According to the national treatment guidelines for
China CARES and the protocol of China CIPRA Sub-
project 4, hematologic parameters, chemistries, preg-
nancy test, liver function tests, amylase activity, and
creatine kinase levels are used for monitoring ARV drug
safety, and CD4 cell count testing is used for monitoring
treatment efficacy. HIV viral load measurement is not
recommended because of the lack of laboratory capacity
in the majority of geographic areas covered by China
CARES. To reflect the actual cost under the national
policy, we did not calculate the costs of HIV viral load
tests.
All expenditures were calculated in US dollars
(US$1 = 7 Chinese Yuan [CNY]). For ARV medications,
expenditures were calculated on the basis of negotiated
prices between provincial health bureaus and participat-
ing pharmaceutical companies. The average daily
expense of ARV regimens was calculated using the total
amount of the individual drug expenditure in 1 year
divided by the total number of treatment days during
the same time period, adjusted for standard dosages.
The expenditure data over different calendar years were
adjusted with a 3% annual inflation rate, using 2004 as
the comparison year.
Statistical analysis
We analyzed the expenditures in the first year after
starting ARV therapy. We calculated the means and
standard deviations (SD) of the total costs, as well as
itemized costs for ARV medications, laboratory testing
and treatment of ADEs and OIs. We further calculated
the costs stratified by study site, demographic variables
and baseline CD4 cell count. The CD4 cell count was
categorized into three strata as follows: <100 cells/μL,
100-200 cells/μLa n d≥200 cells/μL. The Kruskal-Wallis
test was used to evaluate the expenditures associated
with different CD4 cell count categories. Cochran-Man-
tel-Haenszel c
2 tests were used to compare the propor-
tions of costs among the three strata of CD4 cell
counts. The potential independent factors which may
affect the total expenditure included age, gender, treat-
ment site, marital status, ethnic group, level of educa-
tion, occupation, residential status, drug use, CD4 cell
count and incidence of ADEs and OIs. A multivariate
linear regression model was fitted to estimate the inde-
pendent factors associated with total expenditures by
eliminating nonsignificant variables in a stepwise man-
ner. Only the factors significant at a level of 0.05 (two-
tailed) were reported. R/S plus software version 2.8.1
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the analyses.
Results
Demographic Characteristics of Study Subjects
Two hundred seventy-six patients were included in the
analysis. One hundred seventy-six patients (63.8%) were
from Dehong Prefecture of Yunnan Province, including
31 patients (11.2%) from Mangshi County, 32 patients
(11.6%) from Ruili County and 113 patients (41.0%)
from Longchuan County. One hundred patients (36.2%)
were from Wenxi County of Shanxi Province. The aver-
age age of the patients at entry into ARV treatment was
39 years (range, 18-71 years). The patients had the fol-
lowing characteristics: 62% (170/276) were male, 71%
(197/276) were married, 61% (167/276) were majority
Han ethnicity, 21% (57/276) were Jingpo ethnicity, 14%
(40/276) were Dai ethnicity, 4% (12/276) were other
minority ethnicities, 12% (34/276) were illiterate, 45%
(124/276) had an elementary school education, 84%
(232/276) were farmers and 88% (242/276) were living
with their families. Sixty-four patients (23.6%) had a his-
tory of drug use. The means of CD4 cell count to the
time ARV treatment initiated was 181 ± 93 cells/μL
(Table 1).
ARV Treatment and Compliance
Eighty-five percent of patients (235/276) complied with
ARV treatment for 1 year, and 85% of patients (235/
276) remained in treatment or obtained prescriptions.
Five ARV regimens were used by the patients, as fol-
lows: combivir + EFV (36% [100/276]), D4T + 3TC +
NVP (23% [65/276]), AZT + 3TC + NVP (21% [57/
276]), DDI + NVP + 3TC (13% [35/276]) and D4T +
3TC + EFV (7% [19/276]).
Total expenditures
The mean expenditure per patient during the first year
after initiating ARV therapy was US$2,633 (range, US
$226-US$8,679). The total expenditure for all 276
patients was US$726,847; 85.1% of the total expenditure
was spent on ARV medications, 2.5% on medications for
treating ADEs, 1.8% on medications for treating OIs,
7.6% on ARVs laboratory monitoring, 0.4% on labora-
tory tests for diagnosing ADEs, 0.4% for diagnosing OIs,
1.1% on other medical services related to ADEs and
1.0% on other medical services related to OIs (Table 2).
The per capita expenditures were inversely associated
with CD4 cell count (P <0 . 0 1 ) .O na v e r a g e ,p a t i e n t si n
Mangshi had higher expenditures than patients at the
other three sites (P < 0.01). Non-drug users had greater
expenditures than drug users (P < 0.01). The total
expenditure was also associated with the level of educa-
tion, but not associated with age, gender and ethnicity
(Figure 1).
Expenditures on ARVs and safety and efficacy monitoring
A total of US$618,832 was spent on ARVs among the
276 patients in the first year of ARV therapy. The total
expenditure on regular laboratory tests was US$55,281
Table 1 Demographic characteristics of rural Chinese AIDS
patients at entry to antiretroviral therapy, 2004-2006 (N = 276)
Characteristics Number of Patients (%)
Treatment site
Mangshi County, Yunnan Province 31 (11.2)
Ruili County, Yunnan Province 32 (11.6)
Longchuan County, Yunnan Province 113 (41.0)
Wenxi County, Shanxi Province 100 (36.2)
Age (yr)
<30 44 (15.9)
30-44 162 (58.7)
≥45 70 (25.4)
Gender
Male 170 (61.6)
Female 106 (38.4)
Marriage status
Single 27 (9.8)
Married 197 (71.4)
Others 52 (18.8)
Ethnics
Han 167 (60.5)
Jingpo 57 (20.6)
Dai 40 (14.5)
Others 12 (4.4)
Level of education
Illiteracy 34 (12.3)
Elementary School 124 (44.9)
Junior Middle School 84 (30.4)
≥Senior Middle School 34 (12.3)
Occupation
Farmers 232 (84.1)
Others 44 (15.9)
Live with family members
No 34 (12.3)
Yes 242 (87.7)
Drug abuse
No 211 (72.5)
Yes 65 (23.5)
Antiretroviral regimens
AZT+3TC+NVP 57 (20.6)
D4T+3TC+EFV 19 (6.9)
D4T+3TC+NVP 65 (23.5)
DDI+3TC+NVP 35 (12.7)
Combivir+EFV 100 (36.2)
Baseline CD4 cell counts (cells/μL)
<100 57 (20.6)
100-199 103 (37.3)
≥200 116 (42.0)
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$200 (range, US$143-US$313). The total expenditure on
CD4 cell count monitoring, as a part of regular labora-
tory tests, was US$39,429 for all patients (Table 2).
Adverse drug event-associated expenditures
In the first year of ARV therapy, 65.6% of the patients
(181/276) had at least one documented ADE. The most
common ADEs were hepatotoxicity (41.3%), allergic der-
matitis (23.9%), gastrointestinal disorders (21.7%) and
anemia (10.5%; Table 3).
The total expenditure for treating all ADEs was US
$29,703. The medical service expenditure per person for
ADEs in the first year was US$645 for peripheral neuri-
tis, US$127 for hepatotoxicity, US$95 for anemia, US$72
for allergic dermatitis, US$62 for gastrointestinal disor-
ders and US$36 for dizziness and fatigue (Table 3).
The medications used to treat peripheral neuritis were
particularly expensive (US$429 per patient per year).
Huganpian and Gansukeli (two types of traditional Chi-
nese medicine), diammonium glycyrrhizinate (capsules
or injection) and glucurolactone tablets are commonly
used in China to treat hepatotoxicity, with average
expenses of US$4.21 per patient per month. The average
expenditure of diag n o s i n gA D E sr a n g e df r o mU S $ 0 - U S
$17, and other inpatient and outpatient medical service
charges ranged US$3-206, including medical care for
peripheral neuritis (Table 3).
No significant difference was observed in the inci-
dence of ADEs as a function of the CD4 cell count (P =
0.32). Patients with lower CD4 cell counts had signifi-
cantly higher expenditures for medications (P = 0.04),
tests for diagnosing ADEs (P = 0.04), inpatient and out-
patient medical services (P = 0.01) and total medical ser-
vices (P = 0.04) compared to patients with higher CD4
cell counts (Table 4).
Expenditures on OIs
Expenditures for AIDS-related OIs that occurred after
initiating ARV treatment were also reviewed. Among
the 276 patients, 43.84% (121) had at least one diag-
nosed OI in the first treatment year. The most frequent
OIs were respiratory infections (23.6%), diarrhea (7.3%),
fungal infections (6.2%), herpes simplex virus and zoster
infections (4.7%), tuberculosis (TB; 2.5%) and cytomega-
lovirus (CMV) infections (1.8%; Table 3).
The total expenditure for treatment of all OIs in the first
treatment year was US$23,031. The median of all medical
service expenditures per person for OIs in the first year
were as follows: CMV, US$1,208 (acyclovir, ganciclovir
and foscarnet); tuberculosis, US$245 (isoniaizid, rifampin,
pyrazinamide, ethambutol and streptomycin); fungal infec-
tions, US$158 (fluconazole, itraconazole and amphotericin
B); herpes simplex virus and zoster infections, US$107
(acyclovir, ganciclovir and foscarnet); bacterial respiratory
infections, US$85 (oxacillin, efoperazone/sulbactam and
clindamycin); and diarrhea, US$58 (Table 3). The high
cost of treating CMV was largely due to high expenses
associated with medications (median, US$763) and hospi-
talization expenditures (median, US$349).
Those patients with lower CD4 cell counts were more
likely to have at least one OI compared to those with
higher CD4 cell counts (P < 0.01). The OI-related
expenditures among patients with lower CD4 cell counts
Table 2 Expenditures for care of rural Chinese AIDS patients in their first year of antiretroviral therapy (US dollars)
(N = 276)
Expenditure item Calculation formula Total
expenditures
(%)
Average per capita
expenditures
ARV medications (Daily consultative price of ARV regimen) × (days taken actually) $618,832 (85.1) $2,242
Inpatient and outpatient medications for
treating ADEs
(Daily wholesale price of medication for OIs or ADEs) ×
(prescribed dosage)
$18,151 (2.5) $66
Inpatient and outpatient medications for
treating OIs
$12,383 (1.8) $45
ART laboratory monitoring $55,281 (7.6) $200
Inpatient and outpatient laboratory tests
for diagnosing ADEs
Wholesale price for reagent, equipment depreciation, service
charge, charges for use of space, water, electricity
$2,588 (0.4) $9
Inpatient and outpatient laboratory tests
for diagnosing OIs
$2,909 (0.4) $11
Inpatient and outpatient medical service
charges for treating ADEs
$8,964 (1.1) $32
Inpatient and outpatient medical service
charges for treating OIs
Local reference price for items of medical service $7,739 (1.0) $28
Total $726,847
(100.0)
$2,633
ARV, antiretroviral; ART, antiretroviral therapy; ADEs, adverse drug events; OIs, opportunistic infections.
Zhou et al. BMC Medicine 2011, 9:6
http://www.biomedcentral.com/1741-7015/9/6
Page 5 of 10were significantly higher for medications (P < 0.01),
diagnosing OIs (P < 0.01), inpatient and outpatient med-
ical services (P < 0.01) and total medical expenditures
(P < 0.01) compared to patients with higher CD4 cell
counts (Table 4).
Total expenditures and associated factors
Finally, multivariate linear regression analysis indicated
that the following variables were independently asso-
ciated with the total expenditure in the first ARV treat-
ment year: CD4 cell count (100-199 cells/μLv e r s u s
Figure 1 Total expenditure among rural Chinese patients in their first year of antiretroviral therapy.* P < 0.05. N = 276.
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cells/μL: P < 0.004), residence in Mangshi (P < 0.0001),
ADE incidence (P = 0.04) and OI incidence (P = 0.02;
Table 5).
Discussion
This is the first study to determine the expenditure data
for AIDS treatment in rural areas of China. During the
first year, the average annual expenditure for AIDS
treatment per person was US$2,633. Expenditures were
significantly higher for patients with low CD4 cell
counts compared to those with high CD4 cell counts
(P < 0.01). The average expenditures for the treatment
of ADEs and OIs increased significantly among patients
with low CD4 cell counts. Therefore, initiating HAART
to patients with higher CD4 cell counts appears to be
effective in controlling AIDS treatment-related expenses
for ADEs and OIs.
Although funding for HAART has expanded in recent
years, the resources are still limited and costs typically
increase with time. On the basis of our research, the
expenses for ARV medications were the largest compo-
nent of AIDS treatment. Among first-line agents, only
AZT, D4T, DDI and NVP are generic ARVs produced
by pharmaceutical companies in China, while EFV is
purchased by the Chinese central government. Although
3TC was donated by GlaxoSmithKline, we still added its
price into the total expenses to show the actual expendi-
tures for ARVs. The high cost of ARVs has been the
main obstacle for China in considering free second-line
agents. Indinavir without a booster, Kaletra (lopinavir/
ritonavir), tenofovir, emreicitabine and abacavir are used
Table 3 Adverse drug events (ADEs) and opportunistic infections (OIs) associated expenditures among 276 Chinese
patients in their first year of ARV therapy
Categories No. of events (%) Average expenditures (US dollars)
Medications Tests for diagnosis Other medical services Total
ADEs
Hepatotoxicity 114 (41.3) $82 $12 $34 $127
Allergic dermatitis 66 (23.9) $41 $5 $26 $72
Gastrointestinal disorders 60 (21.7) $36 $6 $20 $62
Anemia 29 (10.5) $43 $17 $34 $95
Dizziness and tiredness 14 (5.1) $26 $1 $9 $36
Peripheral neuritis 5 (1.8) $429 $11 $206 $645
Others 12 (4.4) $16 $0 $3 $19
OIs
Fungal Infection 17 (6.2) $88 $11 $59 $158
Respiratory infection 65 (23.6) $52 $9 $24 $85
Tuberculosis 7 (2.5) $128 $48 $70 $245
Diarrhea 20 (7.3) $34 $4 $20 $58
Herpes simplex virus and zoster infection 13 (4.7) $76 $5 $26 $107
Cytomegalovirus infection 5 (1.8) $763 $96 $349 $1,208
Others 11 (4.0) $101 $107 $200 $408
Table 4 Adverse drug events (ADEs) and opportunistic infections (OIs) associated expenditures among rural Chinese
patients, stratified by CD4 cell count (N = 276)
Disease CD4 cell count (cells/μL) Prevalence (%) Expenditures (US dollars)
Medications Tests for diagnosis Other medical services Total
ADEs <100 64.9 (37/57) $92 $14 $37 $142
100-199 71.9 (73/103) $79 $11 $48 $138
≥200 61.2 (71/116) $42 $6 $16 $64
P value 0.32
a 0.04
b 0.04
b 0.01
b 0.04
b
OIs <100 66.7 (38/57) $138 $37 $99 $274
100-199 57.3 (59/103) $30 $6 $14 $51
≥200 19.0 (22/116) $12 $1 $5 $19
P value <0.001
a <0.01
b <0.01
b <0.01
b <0.01
b
aCochran-Mantel-Haenszel c
2 test.
bKruskal-Wallis test.
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available as cost-free treatment. Merito et al. [8] showed
that the average annual cost of ARVs increased with the
duration of treatment, while inpatient costs decreased.
Bruno et al. [9] showed the total expense shifted from
inpatient costs to ARV medication expenses. China will
also face this same issue, along with the progression of
HIV infection and the increasing number of AIDS
patients in the near future. Duraisamy et al. [10] showed
that the median direct cost of treatment and services
was US$610 for 6 months in south India for patients
who received HAART in 2001. According to the report
from the CDC center of the Health Ministry of Iran
[11], the direct cost of HIV treatment was US$1,025 per
person in 2005. A Philippines study [12] reported that
during the early symptomatic stage, the cost per case
per year was US$301, and in the late symptomatic stage
the cost increased to US$5,774 in 1996. Compared with
these studies, the mean expenditure in this study was a
little higher because many patients in the last sympto-
matic stage received HAART at the inception of China
CARES. A greater number of AIDS patients receive
HAART because of free ARVs and reimbursement for
laboratory tests and transportation. Thus, some insur-
ance policy should be developed to lower the patients’
financial burden and promote compliance.
A higher level of education was associated with a
higher cost of HAART-related expenses in our study,
which was consistent with the results of Bozzette et al.
[13]. In rural China, patients with a higher level of edu-
cation may receive more information about AIDS and
related health care policies. Therefore, they may use
more health services than patients with a lower level of
education.
ADEs contribute significantly to HIV/AIDS treatment
costs, which can be mitigated through early symptom
assessment and management. The ADEs associated with
ARVs have been reported in many studies [14-20].
Besides financial constraints, ADEs are also important
factors which affect HAART compliance [21-23], but
few studies have determined the monitoring and treat-
ment expenses of ADEs [24]. We explored the expendi-
tures for ADEs in our study and showed that the
expenditures for the treatment of peripheral neuritis
were the highest because of high costs of medications.
Hepatotoxicity was the most common AIDS-related
ADE, thus regular laboratory monitoring for hepatotoxi-
city in many ARV regimens is standard. NVP was more
likely to induce hepatotoxicity, which is consistent with
studies in China and other countries [14-20]. Expendi-
tures for the treatment of anemia were the third highest
among the ADEs. The main components of the
increased expenditures for the treatment of anemia were
blood transfusion and hospitalization expenditures.
More attention should be paid to regular monitoring of
the blood cell count. Early detection and early treatment
will decrease the expenditure of hospitalization.
HAART has been shown to be effective in increasing
the CD4 cell count and reducing the incidence of OIs
[25-27]. In the current study, OIs still occurred in some
patients who received ARVs. The expenditures for some
OIs with a lower incidence, such as CMV and fungal
infections, were higher than the treatment costs of other
OIs. Long-term hospital stays and higher expenditures
for antiviral and antifungal drugs and special laboratory
tests result in higher expenditures for OIs. HIV/TB
coinfections deserve particular attention because of the
high prevalence and cost. The treatment of HIV/TB
coinfection was the second highest expenditure of all
O I si nt h i ss t u d y .C h i n ah a st h es e c o n d - h i g h e s tp r e v a -
l e n c er a t eo fT Bi nt h ew o r l d .A c c o r d i n gt oaW H O
report [28], the incidence of TB increased at an average
rate of 7% per year in those countries with a high preva-
lence of HIV (≥5%), but the average rate of increase was
only 1.3% in countries with a low prevalence (≤5%).
HIV-infected patients are at a markedly increased risk
for progressive disease following primary TB infection
[29-31]. Thus, screening and treatment of TB at the
time of HIV infection is beneficial to patients and
improves the efficacy of HAART. With respect to the
optimal time to initiate HAART, it is worth noting that
the immune reconstitution syndrome tends to be worse
in patients initiating HAART with lower CD4 cell
counts. Some of the patients in our study were in the
last symptomatic stage, which may increase the inci-
dence of OIs and sequentially increase the expenditure
for treatment.
In this study, we also showed that the incidence of
Pneumocystis carinii pneumonia (PCP) was very low and
may be attributed to regular prophylaxis using
Table 5 Factors associated with total expenditure among
rural Chinese patients in their first year of ARV therapy
(N = 276)
Factors Coefficient Standard
error
F
value
P
value
CD4 cell counts
(cells/μL)
100-199 vs. <100 -280.3 121.0 5.37 0.02
(≥200 vs. <100) -336.4 128.0 8.20 0.004
Treatment site
(Mangshi vs.
others)
582.5 141.3 17.0 <0.0001
Adverse drug event
(Yes vs. no) 186.4 89.5 4.3 0.04
Opportunistic infection
(Yes vs. no) 233.1 95.0 6.0 0.02
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Page 8 of 10sulfamethoxazole. Because the sample size was limited
in our study, the correlation between the use of sulfa-
methoxazole for prophylaxis and the incidence of PCP
should be the subject of study in China.
When to begin HAART is an important issue which
has been much discussed in recent years. Studies in
high-income countries have verified that initiating
HAART in patients with higher CD4 cell counts can
improve the efficacy of treatment [32]. However, for
resource-limited countries, where viral load testing is
often not available for the diagnosis of AIDS, the CD4
cell count and symptoms are the main indicators for
initiating HAART. As a result, some patients are not
diagnosed in a timely manner. A lower CD4 cell count
was associated with higher treatment expenditures. This
effect has also been shown in patients with CD4 cell
counts <50/μl in other studies [13,33]. In our study, we
noted a similar result, although the sample size was lim-
i t e d .O v e rt h el o n gt e r m ,i n i tiating HAART to patients
with higher CD4 cell counts is likely to effectively con-
trol AIDS treatment expenses for ADEs and OIs, but it
will also increase the treatment costs over a longer per-
iod of treatment. Thus, factors, such as the financial
burden of patients, care policy and compliance should
be generally considered when initiating HAART.
I no u rs t u d y ,w ep o o l e dt h ed a t af r o mt w od i s t i n c t
programs, the only difference in program design of
which was the enrollment criteria for CD4 cell counts.
However, the CD4 cell count was similar in the two
programs after considering the WHO’s clinical stages.
Pooling data can increase the sample size and yield
more information about HAARTe x p e n d i t u r e s .M o r e -
over, the price of medications and medical services was
similar in the different sites of the program, although
the different frequencies of follow-up may produce het-
erogeneity in expenses (that is, a greater number of fol-
low-up visits in the China CIPRA).
The main limitation of the study was that the results
cannot be extended to all of China because of the differ-
ences in the cost of living across China [34]. Second,
Chinese public hospitals are classified into three levels
according to the national hospital administration stan-
dard. Higher-level hospitals had more choice of medica-
tions, ancillary examinations and higher medical service
prices. In our study, Mangshi Hospital was the highest-
l e v e lh o s p i t a la n dw a sa s s o c i a t e dw i t hah i g h e rc o s to f
HAART-related expenses. However, other AIDS treat-
ment expense data were from county-level hospitals,
which were usually second-level hospitals. Thus, our
results are likely to have underestimated the costs of hos-
pital care compared with the highest-level hospitals in
cities and overestimate the costs compared with town-
ship hospitals and village clinics. Third, our research did
not address the opportunity cost, expenses outside the
hospital system and the association between compliance
and cost because of the difficulty of collecting data.
Conclusions
Despite the above limitations, this study is the first to
provide important information on the cost of rural
AIDS patients in China. The ARVs expense was the lar-
gest part of HAART cost, averaging US$2,242 per
patient in the first ARV treatment year. These costs
appear to increase over time in China, as consequences
of the increasing number of possible occurrences of
drug resistance in the continuing period of HAART and
more second-line regimens are used. Over the long
term, initiating HAART in patients with a higher CD4
cell count is likely to effectively control AIDS treatment
expenses on ADEs and OIs, but some factors should be
generally balanced when initiating HAART.
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